Clinical Trials Directory

Trials / Completed

CompletedNCT05329701

Individualized Duration of Antibiotic Treatment in Early Onset Infection in Newborns.

Individualized Duration of Antibiotic Treatment in Culture Negative Early Onset Infection in Term Born Newborns: A Nationwide Randomized Controlled Non-inferiority Trial.

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
488 (actual)
Sponsor
Ulrikka Nygaard · Academic / Other
Sex
All
Age
1 Hour – 72 Hours
Healthy volunteers
Not accepted

Summary

A nationwide multicenter open label randomized controlled non-inferiority trial, including 18 departments. The study aims to compare an individualized antibiotic treatment duration with standard seven days of antibiotic treatment for culture negative early-onset infection in term newborns.

Detailed description

There is a documented antibiotic overuse in newborns, and a lack of evidence for the optimal duration of antibiotic therapy in culture-negative infection. The study aims to evaluate the effect of individualized treatment duration in early-onset infection. The study aims to compare an individualized treatment duration with seven days of treatment for culture negative early-onset infection. The investigators hypothesize that the individualized treatment duration, based on structured clinical assessment of symptoms and level of CRP is non-inferior to the standard care being seven days of treatment. In the experimental treatment arm, antibiotics will be stopped when the participant had 24 hours without symptoms and at same time point have decreasing level of CRP, with an absolute threshold of CRP ≤ 30 mg/l. The investigators hypothesize that individualized treatment will shorten the duration of antibiotic therapy in newborns with early onset infection with very little risk of relapse. Newborns who fulfill criteria to stop antibiotics within 48 hours will not be eligible for inclusion.

Conditions

Interventions

TypeNameDescription
OTHERIndividualized treatment duration strategyAs listed under arm description.

Timeline

Start date
2022-04-22
Primary completion
2025-04-05
Completion
2025-08-10
First posted
2022-04-15
Last updated
2026-01-12

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT05329701. Inclusion in this directory is not an endorsement.